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a  b  s  t  r  a  c  t
Relaxin-3  or  insulin-like  peptide  7  (INSL7)  is  the  most  recently  discovered  relaxin/insulin-like  family pep-
tide.  Mature  relaxin-3  consists  of  an  A chain  and a B  chain  held  by  disulphide  bonds.  According  to structure
activity  relationship  studies,  the relaxin-3  B chain  is  more  important  in binding  and  activating  the  recep-
tor.  RXFP3  (also  known  as Relaxin-3  receptor  1, GPCR  135,  somatostatin-  and angiotensin-  like  peptide
receptor  or  SALPR)  was  identiﬁed  as  the  cognate  receptor  for  relaxin-3  by  expression  proﬁles  and  binding
studies.  Recent  studies  imply  roles  of  this  system  in  mediating  stress  and anxiety,  feeding,  metabolism
and  cognition.  Stapling  of  peptides  is a technique  used  to develop  peptide  drugs  for  otherwise  undrug-
gable  targets.  The  main  advantages  of stapling  include,  increased  activity  due  to  reduced  proteolysis,
increased  afﬁnity  to receptors  and  increased  cell  permeability.  Stable  agonists  and antagonists  of  RXFP3
are crucial  for  understanding  the physiological  signiﬁcance  of  this  system.  So far,  agonists  and  antago-
nists  of  RXFP3  are  peptides.  In  this  study,  for the  ﬁrst  time,  we  have  introduced  stapling  of  the  relaxin-3
B  chain  at  14th  and  18th  positions  (14s18)  and  18th  and  22nd  position  (18s22).  These  stapled  peptides
showed  greater  helicity  than  the  unstapled  relaxin-3  B chain  in  circular  dichroism  analysis.  Both  stapled
peptides  bound  RXFP3  and  activated  RXFP3  as observed  in an inhibition  of  forskolin-induced  cAMP assay
and  a ERK1/2  activation  assay,  although  with  different  potencies.  Therefore,  we  conclude  that  stapling
of  the relaxin3  B chain  does  not  compromise  its ability  to activate  RXFP3  and  is  a promising  method  for
developing  stable  peptide  agonists  and  antagonists  of  RXFP3  to  aid relaxin-3/RXFP3  research.
© 2016  The  Author(s).  Published  by  Elsevier  Inc.  This  is an  open  access  article  under  the CC  BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).. IntroductionRelaxin-3 or insulin-like peptide 7 (INSL7) is the most recently
iscovered insulin/insulin-like growth factor/relaxin family neu-
opeptide [1]. Phylogenetic analyses have suggested relaxin-3 to
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/).be the likely ancestor of the relaxin family as it is conserved
from ﬁsh to mammals [2]. Relaxin-3 consists of an A chain (24
amino acids) and a B chain (27 amino acids) held together by
two inter-chain disulphide bonds and one intra-A chain disul-
phide bond [3]. According to structure activity relationship studies,
relaxin-3 interacts with its cognate receptor, the RXFP3 recep-
tor, mainly through the RXXXRXX(I/V) motif of the B chain [1,4].
Relaxin-3 also binds and activates RXFP4 and RXFP1 [5]. In the
mouse, rat and macaque, high levels of relaxin-3 expression
have been observed in the brainstem nucleus in the ventro-
medial dorsal tegmental area commonly known as the nucleus
 under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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ncertus, compared to peripheral tissues [1,6–8]. Projections from
he nucleus incertus have been extensively studied in the rat
9–12].
RXFP3 (previously also known as RXFP Receptor 3, Relaxin-3
eceptor 1, GPCR135, somatostatin- and angiotensin- like pep-
ide receptor or SALPR), a product of a single copy intronless
ene, was identiﬁed as the cognate receptor for relaxin-3 by
xpression proﬁles and binding studies [6,9,10]. In the mouse
nd the macaque, RXFP3 expression has been observed mainly
n the brain, and more discrete RXFP3 expression has been
etected in rat hypothalamic areas such as the paraventricu-
ar nucleus and the supraoptic nucleus [1,6–8,13]. RXFP3 is a
lass A, rhodopsin-like GPCR with a short N-terminal extracel-
ular domain [14]. When stimulated with human relaxin-3 (H3
elaxin), RXFP3 couples to Gi proteins inhibiting cAMP accu-
ulation in RXFP3 stably expressing CHO-K1 cells (CHO-RXFP3)
6,15,16]. In RXFP3 stably expressing HEK293 cells (HEK-RXFP3)
ransiently transfected with Gqi5, Ca2+ mobilization was observed
hen stimulated by H3 relaxin [6,17]. In a separate study using
EK-RXFP3 and CHO-RXFP3 cells, RXFP3 activation by H3 relaxin
ctivated ERK1/2 via the activation of Gi, PI3K, PKC, receptor
nternalization or compartmentalization into lipid rich environ-
ents, and activation of Src tyrosine kinase. Even though these
ignalling events were common in both cell lines, events such
s EGFR transactivation and activation of PLC were observed in
EK-RXFP3 cells and not in CHO-RXFP3 cells. Moreover, the latter
ignalling events were also observed in the murine SN56 cell line
15].
The conserved distribution of the relaxin-3 and RXFP3 sys-
em together with behavioural and biochemical studies implies
oles for this system in mediating stress and anxiety [18,19],
eeding and metabolism [20–25] and cognition [26,27]. Thus, sta-
le agonists and antagonists of RXFP3 will be excellent tools for
nderstanding the mechanism behind these responses and treating
tress, feeding and cognition related disorders associated with the
elaxin-3/RXFP3 system. Recent advances in developing agonists
nd antagonists of RXFP3 include a small molecule allosteric mod-
lator of RXFP3 that functions only with the non-native amidated
orm of the orthosteric agonist H3 relaxin [28] and so has limited
tility as a drug, and the development and uses of chimeric peptide
gonists and antagonists, and peptide agonists with C-terminally
runcated B chains [29–32]. Being peptides, most of these ligands
ave low stability due to degradation by proteases. Moreover, pep-
ide ligands can only be administered via intracerebroventricular
njections to target the CNS, as systemically administered peptides
ay  not cross the blood brain barrier. In this context, hydrocarbon
tapling of peptide ligands will be a useful method of develop-
ng peptide drugs to overcome challenges faced in targeting the
NS, as stapled peptides, locked in their conformations are highly
table and less prone to proteolytic degradation and are able to
fﬁciently penetrate cells [33]. As mentioned previously, relaxin-3
ctivates RXFP3 by its B chain, and the A chain acts as a scaf-
old to stabilize or “staple” the -helix of the B chain (Fig. 1A
nd Ci) [4]. Thus we hypothesized that the B chain of relaxin-
 may  be stabilized in its -helical conformation with the use
f hydrocarbon stapling which will mimic  the presence of the A
hain.
Here we report, stapling of the relaxin-3 B chain and testing the
tapled peptides for their biological activity. We  employed optical
ichroism, ligand binding assays, signalling assays based on RXFP3
oupling to Gi/o and ERK1/2 activation to assess the secondary
tructure and thermal stability of stapled B chains of relaxin-3
nd their ability to bind and activate RXFP3. Some of the results
eported here were previously communicated in a meeting abstract
34].s 84 (2016) 44–57 45
2. Materials and methods
2.1. Materials
RXFP3 stably expressing HEK293T cells (HEK-RXFP3), CHO-
K1 cells (CHO-RXFP3) and RXFP3 endogenously expressing SN56
cells were provided by Prof. Roger Summers (Monash Institute of
Pharmaceutical Sciences & Department of Pharmacology, Monash
University) and Prof. Ross Bathgate (Florey Institute of Neuro-
science and Mental Health, University of Melbourne). HEK293T
(wild type) cells were provided by Prof. Lawrence Stanton (Genome
Institute of Singapore). Human relaxin-3 (H3 relaxin) was  pur-
chased from Peprotech Inc. (cat. no.130-10, USA). DMEM,  TripLE,
Hygromycin B was from Life Technologies (USA), fetal bovine serum
(FBS) was  from Life Technologies (South America), poly-l-lysine
(PLL), 3-isobutyl-1-methylxanthine (IBMX) and bovine serum albu-
min  (BSA) were from Sigma (Saint Louis, USA). Dimethyl sulfoxide
(DMSO) was  from MP  Biomedicals (Solon-Ohio, USA). Forskolin
was from Tocris Bioscience (Bristol, UK), The cyclic AMP  (cAMP)
enzyme immunoassay (EIA) kit was from Cayman Chemicals (Ann
Arbor, MI), and hydrochloric acid (HCl) was from BDH Chemicals
Ltd. (UK). Sodium dodecyl sulphate (SDS) lysis buffer (4x) was  pre-
pared using 2 M dithiothreitol to a ﬁnal concentration of 0.4 M
(Goldbiotechnology, USA), 1 M TrisHCl, pH 6.8 to a ﬁnal concentra-
tion of 0.313 (1st BASE, Singapore), 10% SDS (w/v) (Bio-Rad- USA),
50% glycerol (v/v) (Sigma, Saint Louis, USA) and 0.05% (w/v) bro-
mophenol blue (Bio-Rad). Immun-Blot® PVDF membranes were
from Bio- Rad (USA), 30% acrylamide and bis-acrylamide solu-
tion, 37.5:1 was  from Bio-Rad (China), ammonium persulphate
were from Bio-Rad (Japan), 1.5 M TrisHCl, pH 8.8, 0.5 M TrisHCl,
pH 6.8, tris glycine buffer, tris glycine-SDS buffer, tris-Buffered
Saline (TBS) were from 1stBase (Singapore), Tetramethylethylene-
diamine (TEMED) was from Life Technologies (USA). Tween 20 was
from Sinopharm Chemical Reagent Co, Ltd. (China). Anti-phospho
p44/p42 MAPK (ERK1/2) (Cat. No. 4370S) and anti-p44/p42 MAPK
(ERK1/2) (Cat. No. 4370S) were from Cell Signalling Technology.
Goat anti-rabbit HRP conjugated secondary antibodies (cat. no.
31460) were purchased from Thermo Scientiﬁc. Luminata forte
western HRP substrate was from Merk Millipore (Billeria, MA,  USA).
RestoreTM Western blot striping buffer was from Thermo Fischer
Scientiﬁc (Rockford, USA). Cell culture ﬂasks and plates were from
Greiner Bio-One (Germany).
2.2. Designing and modelling of the stapled peptides
Relaxin-3 binds to RXFP3 by RXXXRXX(I/V) motif of the B chain
[1]. Moreover residues R8, R12, I15, R16, and F20 of the relaxin-
3 B chain helix are reported to be important in binding to RXFP3
and C terminal residues R26 and W27  are important in activat-
ing the receptor (Fig. 1Cii) [32,35]. Based on this knowledge, we
designed two  stapled peptides which were stapled at 18th and 22nd
positions (18s22) (Fig. 1Civ) and 14th and 18th positions (14s18)
(Fig. 1Cv). Residues involved in stapling were chosen so that they
will not interfere with residues important in receptor binding and
activation and to mimic  the disulphide bond formation of the A
chain in the native relaxin-3. Cys residues at positions 10 and 22
were mutated to Ser to prevent cyclization and oligomerization
of the peptides. A corresponding relaxin-3 B chain double mutant
(Fig. 1Cii) was synthesised as an unstapled peptide control.
The nuclear magnetic resonance (NMR) structure of relaxin-3
(PDB entry 2FHW) [36] was prepared using the Protein Prepara-
tion Wizard in Maestro version 10.3 (Schrodinger LLC, New York,
USA]). This preparation process is necessary to ensure structural
correctness. NMR  analysis produces a set of estimates of constraints
on distances between atoms resulting in an ensemble of mod-
els rather than a single structure. The 2FHW structural ensemble
46 T. Jayakody et al. / Peptides 84 (2016) 44–57
Fig 1. (A) Schematic representation of ribbon structure of relaxin-3. (B) Strategy for designing the stapled B chains of relaxin-3 by ring-closing metathesis to staple the
-helix  of the B chain of relaxin-3 by i and i + 4 stapling. (C) (i) Sequence of the A and B chains of human relaxin-3 (H3) held by two inter-chain disulphide bonds and one
intra-A  chain disulphide bond; (ii) sequence of the wild type B chain of relaxin-3 (B chain WT); (iii) sequence of the relaxin-3 B chain Cys10Ser + Cys22Ser double mutant (B
chain  DM); (iv) sequence of the 18s22 stapled B chain of relaxin-3 stapled at 18th and 22nd position by i and i + 4 stapling (18s22); and (v) sequence of the 14s18 stapled B
chain  of relaxin-3 stapled at 14th and 18th position by i and i + 4 stapling (14s18). Residues highlighted in green are involved in RXFP3/RXFP4 activation, residues highlighted
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ontains 20 such models for relaxin-3. The preparation process
ncluded setting the tautomer and protonation state of the peptide
nd subjecting each of the 20 structures to restrained minimiza-
ion using an optimized potentials for liquid simulations (OPLS)
orce ﬁeld [37], speciﬁcally the OPLS3 force ﬁeld optimized to pro-
ide broad coverage of drug-like small molecules and proteins [38],
nd a generalized Born model of solvation augmented with the
ydrophobic solvent accessible surface area term (GB/SA solva-
ion model). Structures 1, 10 and 20 were selected for molecular
ynamics (MD) simulations using both intact relaxin-3 with the
 and B chains together or the B chain only. Both the wild type
elaxin-3 B chain and a relaxin-3 B chain Cys10Ser + Cys22Ser dou-
le mutant (double mutant) (Fig. 1Ciii) were investigated. The
esmond System Builder version 4.3 (Schrodinger LLC) was used
o build a solvated system for the simulation including the solute
eptide and the solvent water molecules with counter ions. We
sed that ﬂexible simple point charge (SPC) water model for the
olvent with orthorhombic boundary conditions and a 10 Å buffer.
he systems were neutralized with Cl− ions and 0.15 M NaCl salt
as added. The systems were then relaxed and subjected to 12 ns
D using the OPLS3 force ﬁeld and a substance (N), pressurevolved in RXFP3 binding only [35]. (For interpretation of the references to color in
(P) and temperature (T) [NPT] ensemble class with T = 300 K and
P = 1.01325 bar. The stapled peptides were built using the relaxin-
3 B chain Cys10Ser + Cys22Ser double mutant of structures 1, 10
and 20 of the 2FHW structural ensemble and prepared as described
above. The staple and the two amino acids involved in stapling were
relaxed using 200 steps of Polak-Ribiere conjugate gradient (PRCG)
minimization, the OPLS3 force ﬁeld and the GB/SA solvation model
while the remaining residues were constrained. Systems were then
build and these were subjected to 12 ns MD as described above.
2.3. Stapled peptides
Hydrocarbon stapling of the designed relaxin-3 B chains
was carried out by substituting the amino acids at i(14) and
i + 4(18) positions or i(18) and i + 4(22) positions with (S)2-(4′-
pentenyl)alanine and subsequent ring-closing metathesis (RCM).
Biosynthesis Inc. (USA) was  contracted to synthesise these pep-
tides. The molecular weight and purity of the peptides were
analysed by mass spectrometry and RP- HPLC by Biosynthesis Inc.
(USA).
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.4. Circular dichroism
Circular dichroism (CD) experiments were carried out using a
asco 815 spectrometer (Tokyo, Japan). The ﬁnal peptide concen-
ration was kept constant (0.20 mg/ml) for all the peptides studied.
o determine the -helicity of the synthesised peptide samples,
D spectra were collected from 190 to 260 nm using a 0.1 cm path
ength quartz cuvette at room temperature. We  used a continu-
us scan with a 20 nm/min scanning speed with a response time
f 0.5 s, 0.5 nm step resolution and 1 nm spectral band width. All
eptide samples were measured in water with the peptide concen-
ration ranging from 50 to 65 M.  The spectra were generated as an
verage of 3 independent scans. After baseline correction, the ﬁnal
pectra were expressed as a molar ellipticity  (deg cm2 dmol−1)
er residue. All spectra were converted to a uniform scale of
olar ellipticity after background subtraction. Curves shown are
moothed with standard parameters.
The mean helical content of the peptide samples was calculated
sing the mean residual ellipticity at 222 nm:
helicity = 100[222 nm/(40, 000(1 − 2.5/n))]
here n is the number of amino acid and 222nm is the mean resid-
al ellipticity at 222 nm [39–41].
.5. Variable temperature circular dichroism
The variable temperature CD (VT-CD) experiments were per-
ormed on a Jasco J-815 spectropolarimeter equipped with a peltier
et up. The peptides were dissolved in water with the concentra-
ion ranging from 50 to 65 M.  A quartz cuvette with the path
ength of 0.1 cm was used. For the wavelength scan, spectra were
onitored over the 190–260 nm range with a resolution of 0.2 nm
nd a band width of 1 nm.  Temperature-dependent CD spectra of
ach peptide were scanned at 5 ◦C intervals over a temperature
ange of 20–90 ◦C from 190 to 260 nm.  To generate thermal unfold-
ng curves, the ellipticity at 222 nm was measured every 5 ◦C from
0 to 90 ◦C with a temperature slope of 1 ◦C/min. Experiments at
ach temperature were recorded after 30 min  to allow for equi-
ibrium in the sample cell. The spectra presented are an average
f 3 independent scans with a scan speed of 20 nm/min. Replicate
easurements as a function of temperature reproduced the spec-
ra within ±5% after the heating cycle. For the single wavelength
easurements at 222 nm,  the heating rate was 0.5 ◦C/min over a
emperature range of 20–90 ◦C and 90–20 ◦C [42].
.6. Characterization of unfolding by following the change in
llipticity at a single wavelength As a function of temperature
When the CD of a protein changes as a function of temperature,
he change is utilized to analyse the thermodynamics of unfolding
r folding. In the simplest case, a molecule undergoes an unfolding
ransition between two states: folded, F, and unfolded, U. At any
emperature, T, the constant of folding is, K, is:
 = [F]/[U]
F] and [U] are the concentrations of the folded and unfolded forms
espectively. The fraction folded at any temperature is .
 = [F]/([F] + [U])
 = (t − U)/(F − U)t is the observed ellipticity at any temperature, F is the elliptic-
ty of the fully folded form and U is the ellipticity of the unfolded
orm. To ﬁt the change of CD at a single wavelength as a func-
ion of temperature, T (Kelvin), the Gibbs–Helmholtz equation thats 84 (2016) 44–57 47
describes the folding as a function of temperature was  applied
[43–46].
2.7. Assay for proteolytic stability of peptides
14s18 (3014.49 Da) and B chain DM (3010.18 Da) peptides
reconstituted in water with 0.1% of BSA (66.5 kDa) were digested
with sequencing grade endoproteinase Glu-C (glutamly endopep-
tidase, EC 3.4.21.9; Promega, Madison WI,  USA) in a 1:10 enzyme
to peptide ratio by incubating for 1 h at 37 ◦C along with peptide
and enzyme only control reactions. The reactions were terminated
by adding equal volumes of X2 Tricine Sample Buffer (Bio-Rad, CA,
USA) supplemented with 2% v/v -mercaptoethanol (Sigma) and
boiling at 100 ◦C for ﬁve minutes. Products of the digestion and
control reactions were then resolved in a 20% Tris-tricine gel and
stained by Coomassie Brilliant Blue R-250 staining solution (Bio-
Rad, CA, USA) after incubating in a ﬁxing solution composed of
10% acetic acid and 40% Methanol. Coomassie stained gel image
was acquired after destaining with Coomassie Brilliant Blue R-250
Destaining Solution (Bio-Rad, USA) [47].
2.8. Cell culture
HEK293T cells stably expressing RXFP3 (HEK-RXFP3), CHO-K1
cells stably expressing RXFP3 (CHO-RXFP3), HEK293T (wild type),
CHO-K1 (wild type) and SN56 cells were maintained in DMEM,
10% (v/v) FBS and 1× penicillin/streptomycin (10,000 U/ml) at
37 ◦C in a 5% CO2 humidiﬁed environment. Each cell line was pas-
saged using TripLE at 80% conﬂuency. In addition, hygromycin
B (400 ng/ml) was used to supplement media used in maintain-
ing CHO-RXFP3 cells. For performing the receptor-ligand binding
assays and protein estimation, HEK-RXFP3 cells were harvested at
90% cell conﬂuency for plating onto PLL pre-coated 96-well plates.
2.9. Receptor binding assay
2.9.1. Peptide synthesis and characterization
R3 B1-22R peptide was prepared by Fmoc-based solid phase
peptide synthesis using standard methods with single coupling
reactions and puriﬁed using RP-HPLC resulting in a high purity
(>95%) product (Biosynthesis Inc., USA). The lanthanide chelat-
ing agent, DTPA (diethylenetriaminepentaacetic acid), was  coupled
with R3 B1-22R and after puriﬁcation DTPA-R3 B1-22R was  incu-
bated with an excess of EuCl3, until the complex between DTPA
and Eu+3 was formed. The ﬁnal peptide product was  evaluated by
matrix-assisted laser desorption-ionization/time-of-ﬂight reﬂex
mass spectrometry (MALDI-TOF-MS), revealing a 1:1 molar ratio
of Eu-DTPA labelling to the R3 B1-22R peptide (observed (m/z)
2998.42, theoretical (m/z) 3145.38). However, during the MALDI-
TOF-MS analysis, the Eu(III) group was dissociated partially and
therefore 2 peaks were seen. This only occurred during the MALDI-
TOF-MS analysis. In contrast, the peptide puriﬁed by RP-HPLC
displayed a single peak with a high purity proﬁle (>95%) product.
The ﬁnal peptide product Eu-DTPA-R3 B1-22R was solubilised in
a triethylaminoacetate buffer (pH ∼7), to prevent the liberation of
europium from DTPA. The speciﬁc activity of Eu-DTPA-R3 B1-22R
was estimated to be 1 × 105 ﬂuorescence units (FU)/pmol based on
the biological activity of the fraction.
2.9.2. Eu(III)-based ligand binding assays
Cells were plated in 96-well plates at a density of
25,000 cells/well. On the day of experiment, media was aspi-
rated from all wells prior to the addition of the ligands to be tested.
Ligands were diluted in binding media (DELFIA L*R binding buffer
concentrate 10×,  diluted 1:10 containing the following ﬁnal con-
centrations: 50 mmol/l Tris-HCl, 5 mmol  MgCl2, 25 mol/l EDTA,
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.2% BSA) and samples were tested in triplicates, unless otherwise
oted. Saturation binding assays were carried out as follows:
ncreasing concentrations of Eu-DTPA-R3 B1-22R (0.5–128 nM)
eptide were added to the cells and incubated for 2.5 h with gentle
haking (∼50 rpm) at room temperature. Non-speciﬁc binding was
etermined in the presence of 1 M unlabelled R3 B1-22R. After
inding at room temperature for 2.5 h, the binding solution was
emoved and cells were washed twice rapidly (∼0.5 s) with ice cold
BS. Following the washing step, the enhancement solution (1244-
04, Perkin Elmer) was added directly to the wells (150 l/well)
nd the plates were incubated for 30 min  at 37 ◦C prior to reading.
he plates were read on a Wallac VICTOR3 instrument using the
tandard Eu(III) TRL measurement (340 nm excitation, 400 sec
elay, and emission collection for 400 s at 615 nm).
For competition binding, eight different concentrations of non-
abelled R3 B1-22R (1 pM to 10 M)  and intact human relaxin-3
H3; 1 pM to 10 M),  and nine different concentrations of relaxin-
 B chain Cys10Ser + Cys22Ser double mutant (B chain DM;  1 pM to
00 M),  18s22 stapled relaxin-3 B chain (18s22; 1 pM to 100 M)
nd the 14s18 stapled relaxin-3 B chain (14s18; 1 pM to 100 M)
nd a ﬁxed concentration of Eu-DTPA-R3 B1-22R (8 nM)  were uti-
ized using an otherwise identical procedure and conditions to
hose described above. Each condition was run in triplicate and
ach experiment was repeated at least three times.
.10. ERK1/2 activation assay
ERK1/2 activation was detected by a Western blot based method
48]. To determine the time course of ERK1/2 activation by
3 relaxin, HEK-RXFP3, CHO-RXFP3, HEK293T and CHO-K1 cells
5 × 105 cells/well) were plated in 12 well plates with DMEM,  10%
BS and penicillin/streptomycin. The next day, cells were serum
tarved for 3–4 h in 450 l of DMEM.  After starvation, the cells
ere treated with 10 nM H3 relaxin for time points ranging from
 to 35 min  to determine the time course of ERK1/2 activation
r with the stapled peptides at indicated concentrations. At the
nd of each time point, the reaction was stopped by immedi-
tely lysing the cells using 2× SDS loading buffer. The cells were
craped and lysates were transferred to microfuge tubes in ice.
he lysates were boiled at 100 ◦C for 10 min  and electrophoresed
hrough 8% SDS-Polyacrylamide gels for 2 h at 100 V. Next, proteins
ere transferred to a PVDF membrane for 75 min  at 110 V followed
y blocking with 5% BSA in TBS/Tween 20 and immunoblotting for
otal ERK1/2 (tERK1/2) using Anti-p44/p42 MAPK (ERK1/2) diluted
:1000 in 1% BSA in TBS/Tween 20 and goat anti-rabbit HRP conju-
ated IgG secondary antibody diluted 1:5000. Protein bands were
isualized by chemiluminescence using Luminata Forte HRP sub-
trate. After visualization, primary and secondary antibodies were
tripped using RestoreTM Western blot striping buffer and reprobed
sing Anti-phospho p44/p42 MAPK (ERK1/2) diluted 1:1000 and
isualized as described above.
.11. Inhibition of forskolin-induced cAMP assay
The cAMP assay was performed essentially as previously
escribed [49]. Brieﬂy, cells (1 × 105/well) were plated in PLL coated
4 well plates. The following day, cells were serum starved with
25 l of serum free DMEM for six hours. At the end of starvation,
ells were treated in triplicate with H3 relaxin, stapled peptides,
r vehicle [15] at indicated concentrations for 5–10 min, and then
ith forskolin (3–5 M)  or vehicle (control) for 15 min  in 37 ◦C.
t the end of the incubation, the cells were lysed by shaking with
0 l 0.1 M HCl for 20 min  after which the cells were scraped and
entrifuged at 1000g for 10 min  to pellet the debris. From the super-
atant, 50 l was applied on the mouse anti-rabbit IgG pre-coated
late and assayed according to the manufacturer’s instructionss 84 (2016) 44–57
(Cyclic AMP  EIA Kit, Cayman Chemicals). To estimate the EC50,
intact human relaxin-3 (H3) was  applied at six concentrations rang-
ing from 1 pM to 100 nM and relaxin-3 B chain Cys10Ser + Cys22Ser
double mutant (B chain DM)  and the 14s18 stapled relaxin-3 B chain
(14s18) were applied at six concentrations ranging from 100 pM to
10 M on both HEK-RXFP3 cells and wild type HEK293T cells.
2.12. Data analysis
For the ligand binding assays, all statistical analysis was evalu-
ated with GraphPad Prism using appropriate non-linear regression
analyses. Binding data are presented as mean ± SEM. Speciﬁc bind-
ing data were ﬁtted using non-linear regression and a one-site
binding model using the following four-parameter Hill equation
Y = Bottom + (Top-Bottom)/(1 + 10(ˆLogEC50-X)) in GraphPad Prism.
Competitive binding experiments were ﬁtted to a one-site binding
model and pKi calculated using the Kd value of 34.64 nM deter-
mined from the saturation binding. In the ERK1/2 activation assay,
the density of phospho ERK1/2 and total ERK1/2 was determined
by ImageJ software and density of phospho ERK1/2 was  normal-
ized by total ERK1/2. Data for three independent experiments were
analysed by the Kruskal-Wallis test followed by Dunn’s multiple
comparisons test using GraphPad Prism. A non-parametric test was
applied because the control data did not meet the criterion for para-
metric distribution. In the inhibition of forskolin-induced cAMP
assay, the cAMP concentrations were calculated using a cAMP stan-
dard curve (0.3–750 nM). The data from three experiments were
analysed using one-way ANOVA followed by Tukey’s (when the
mean of each group is compared with means of every other group)
or Bonferroni’s post hoc (when means of selected groups are com-
pared) test using GraphPad Prism. The concentration-response data
were analysed by non-linear ﬁtting and estimation of pEC50 in
GraphPad Prism.
3. Results
3.1. Modelling and synthesis of the stapled peptides
The root mean square ﬂuctuation (RMSF) is useful for identi-
fying the parts of the peptide that is more or less ﬂexible during
the MD simulation and to compare the ﬂexibility of different pep-
tides. In Supplementary Fig. 1, the RMSF averaged is plotted against
residue index for the B chain of intact human relaxin-3, the wild
type relaxin-3 B chain in isolation, the double mutant of the relaxin-
3 B chain in which the Cys residues at positions 10 and 22 were
mutated to Ser to prevent cyclization and oligomerization of the
peptides, and the two  stapled peptides. The isolated relaxin-3 B
chains have higher RMSF than the intact human relaxin-3 con-
tain both the A chain and the B chain indicating that the A chain
provides some stabilization especially of the central part of the B
chain. The 14s18 stapled peptide has similar RMSF as the double
mutant and native B chain. The 18s22 stapled peptide has signiﬁ-
cantly lower RMSF than wild type and double mutant relaxin-3 B
chain indicating a rigidifying effect of the staple.
The protein secondary structure elements (SSE) distribution was
monitored throughout the simulation. These are -helixes as no
beta strands are present in the B chain of relaxin-3. SSE’s were plot-
ted versus residue index and graphs for the chain B of intact human
relaxin-3, wild type relaxin-3 B chain, double mutant relaxin-3 B
chain and the two stapled peptides are shown in Supplementary
Fig. 2. These plots are useful for determining if the stapling stabilizes
the helical part of the protein. Intact human relaxin-3 containing
both the A chain and the B chain is the structure that is most helical
but only slightly more than the native relaxin-3 B chain and double
mutant B chain. The 14s18 stapled B chain was a helical peptide
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ith only the part between the staple maintaining the secondary
tructure. The 18s22 stapled peptide was predicted to be as helical
s the native B chain peptide and in the modelling it was  the most
igid of all single chain peptides as indicated by the lowest RMSD.
The stapled peptides were synthesised by substituting the
mino acids at i(14) and i + 4(18) positions or i(18) and i + 4(22)
ositions of the relaxin-3 B chain with (S)2-(4′-pentenyl)alanine
nd subsequent RCM (performed by Biosynthesis Inc., USA). The
olecular weight and purity of the peptides were analysed by mass
pectrometry and RP- HPLC. Mass spectrometry analysis revealed
hat the observed mass of 18s22 and 14s18 were 3074.19 and
014.95 respectively. The purity as analysed by RP-HPLC was  >97%
or 18s22 and >95% for 14s18. The peptide puriﬁed using RP-HPLC
isplayed a single peak with a high purity proﬁle (>95%) product.
n many cases, the RCM reaction yields one major oleﬁn isomer,
hich is often difﬁcult to identify, and in this case, the short (i to
 + 4) stapling approach in principle avoids the incidence of cis/trans
somerization within the rings. Thus, it is likely that the single RP-
PLC peak represents a predominance of one major oleﬁn isomer.
e did not however isolate or identify a speciﬁc isomer.
ig. 2. (A) Circular dichroism (CD) spectra of intact human relaxin-3 (H3; green), the rela
tapled relaxin-3 B chain (18s22; orange) and the 14s18 stapled relaxin-3 B chain (14s18; b
0.2  mg/ml). H3 is comprised of both the A chain and B chain and the CD spectra reﬂects a
M  is consistent with this peptide being a relatively unstructured random coil. The CD s
tability of the 14s18 stapled peptide was assessed by variable temperature (VT)-CD sp
ntervals over a temperature range of 20–90 ◦C at wavelengths from 190 to 260 nm.  Data
0 ◦C (green). The peptide was dissolved in water with the concentration ranging from 
he  ellipticity at 222 nm was  measured every 5 ◦C from 20 to 90 ◦C with a temperature sl
he  spectra plotted are an average of 3 independent scans with a scan speed of 20 nm/m
eferences to color in this ﬁgure legend, the reader is referred to the web version of this as 84 (2016) 44–57 49
3.2. Conformational analysis of the stapled peptides
Secondary structure of peptides was determined by CD spec-
troscopy in the far-UV spectral region (190–260 nm). At these
wavelengths the chromophore is the peptide bond, and the signal
arises when it is located in a regular, folded environment. -helix,
ß-sheet and random coil structures give rise to characteristic CD
spectrum. The mean residual molar ellipticity of each secondary
structure type in the peptides depicts the characteristic curve of an
-helix for the 14s18, 18s22 stapled peptides whereas the relaxin-
3 B chain double mutant has a random coil structure and the intact
human relaxin-3 containing both the A chain and B chain has a
mixture of -helix and ß-sheets (Fig. 2A).
CD was  employed to determine the mean helical content of
the stapled peptides, 14s18 and 18s22, along with the relaxin-3
B chain double mutant as a control unstapled peptide. Differences
in 222 nm indicate change in helical content and can be used to
determine a percentage helicity value. We calculated percentage
helicity (Table 1) as previously described [39,40]. 14s18 had an
enhanced -helicity proﬁle of 18.5% helical content compared with
the 1.80% helical content of the unstapled peptide. 18s22 had also
xin-3 B chain Cys10Ser + Cys22Ser double mutant (B chain DM; purple), the 18s22
lue). All compounds were prepared in water with concentration adjusted to 62.5 M
 complex mixture of secondary structural conformations. The CD spectra of B chain
pectra of 18s22 and 14s18 indicate the presence of -helicity. (B) Thermodynamic
ectral analysis. (i) The temperature-dependent CD spectrum was  scanned at 5 ◦C
 are plotted for 20 ◦C before heating (blue), at 90 ◦C (dark red) and after cooling to
50 to 65 M.  (ii) Changes in CD intensity at 222 nm as a function of temperature.
ope of 1 ◦C/min during heating (black squares) and cooling (grey diamonds) cycles.
in and are expressed as mean residual weight ellipticity. (For interpretation of the
rticle.)
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Table 1
Percentage helicity of non-stapled and stapled relaxin-3 B chain peptides as deter-
mined by analysis of circular dichroism (CD).
Peptide 222 nm % helicity
B chain DM −650.5999 1.80
18s22 −2240.0269 6.17
14s18 −6720.0969 18.51
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Fig. 3. Hydrocarbon stapling of the B chain of relaxin-3 protects against proteolysis.
Coomassie Brilliant Blue R-250 stained tricine SDS-PAGE of endoproteinase Glu-C
with and without BSA and 14s18 stapled relaxin-3 B chain (14s18) and relaxin-3
B  chain Cys10Ser + Cys22Ser double mutant (B chain DM)  with and without Glu- chain DM:  relaxin-3 B chain Cys10Ser + Cys22Ser double mutant; 18s22:18s22
tapled relaxin-3 B chain; 14s18: 14s18 stapled relaxin-3 B chain.
n enhanced the helicity proﬁle albeit much lower than 14s18 with
.2% helical content.
.3. Thermal melts as a measure of stability
As the CD spectra data indicated that 14s18 was  the most helical
f the stapled peptides we selected this peptide for determination
f thermal stability by CD analysis. The random coil structure of
ontrol relaxin-3 B chain double mutant was not sufﬁciently heli-
al to generate meaningful thermal stability data by CD analysis.
or most peptides, secondary structure is lost upon unfolding and
he far-UV CD spectra of a folded and unfolded peptides are dis-
inct. We  obtained the thermodynamics of peptide unfolding by
a) collecting the complete spectra (190–260 nm)  as a function of
emperature and (b) by measuring the intensity of the CD signal at
 ﬁxed wavelength (e.g. 222 nm for an -helical protein) as a func-
ion of temperature giving a measure of thermal stability. The full
pectra (190–260 nm)  of 14s18 at 20 ◦C shows the ordered struc-
ure of an -helical peptide and the peptide unfolds when it is
radually heated from 20 to 90 ◦C (Fig. 2Bi). At 90 ◦C it is partially
nfolded as indicated by an upward shift in the CD band, however it
egains back its folded conformation when it is cooled down from
0 to 20 ◦C (Fig. 2Bi), suggesting thermally stable and reversible
onformational transition.
We  also characterized the unfolding by following the change in
llipticity at 222 nm to determine whether a peptide has unfold-
ng or folding intermediates. As shown in Fig. 2Bii, a linear increase
f the ellipticity at 222 nm for 14s18 has been observed for both
eating and cooling with a slope of 20.86 ± 1.324 (for heating) and
3.47 ± 1.519 (for cooling) degcm2dmol−1 ◦C−1 (Fig. 2Bii). At higher
emperatures, the decrease in CD ellipticity indicates that the pep-
ide is partially unfolded and the linear dependency also indicates
ess energy difference between the two states.
We further used this information to predict the melting tran-
ition point [50] for 14s18 stapled peptide during unfolding
ransition between two states: folded, F, and unfolded, U. TM of
he 14s18 falls near to (50–55 ◦C) whereas the relaxin-3 B chain
ouble mutant did not have a cooperative melting transition point
n this temperature range, and therefore its melting temperature
as indeterminable by this method.
.4. Proteolytic stability assay
In order to compare the proteolytic stability of the 14s18 stapled
elaxin-3 B chain with the relaxin-3 B chain double mutant, we
ncubated equal amounts (g) of the peptides with endoproteinase
lu-C isolated from Staphylococcus aureus V8 that is predicted by
he ExPASy Peptide Cutter software to cleave the B chain double
utant at the Glu residue at the 13th position to give two products
f 1597 Da and 1432 Da. 14s18 incubated with endoproteinase Glu-
 remained intact while the B chain double mutant was  digested
o produce <2 kDa products (Fig. 3). These data are consistent with
he prediction that hydrocarbon stapling stabilizes the relaxin-3 B
hain against proteolysis.C  incubated at 37 ◦C for 1 h. 14s18 incubated with endoproteinase Glu-C remains
intact while the B chain DM is digested to produce <2 kDa products.
3.5. Ligand binding assays
R3 B1-22R has been reported to be a selective RXFP3 ligand
[30]. We had applied a site-directed synthesis strategy to chelate
Eu-DTPA to the N-terminus of single chain R3 B1-22R. Assays
using Eu-chelate-peptides have been reported to be highly repro-
ducible, showed excellent signal-to-noise ratios and were faster
than radioisotope-based assays and in other cases DTPA labelling
of bioactive peptide has been described [51–53]. The pharmaco-
logical proﬁle of Eu-DTPA-R3 B1-22R was characterized by both
saturation and competition binding assays.
3.5.1. Saturation binding assay
To test whether Eu-DTPA-R3 B1-22R had receptor binding activ-
ity, we  ﬁrst carried out a saturation binding assay using HEK293T
cells stably expressing RXFP3 (HEK-RXFP3) (Fig. 4A). To determine
the total binding, cells were incubated with different concentra-
tions of Eu-DTPA-R3 B1-22R in a 96 well plate, and to measure the
non-speciﬁc binding 1 M of unlabelled R3 B1-22R was  used. The
non-speciﬁc binding was  found to be substantially less than total
binding at all concentration of Eu-DTPA-R3 B1-22R tested (Fig. 4B).
Eu-DTPA-R3 B1-22R binds in a speciﬁc and saturable manner and
ﬁtted best to a one-site binding model in the hyperbolic ligand bind-
ing function Y = BmaxX/(Kd + X) (Fig. 4C). The calculated dissociation
constant (Kd) for Eu-DTPA-R3 B1-22R was 34.64 ± 3.83 (n = 3) and
the maximal binding (Bmax) was  1061 (fmol/mg) ± 46.68 (n = 3) as
shown in Fig. 4C, suggesting that Eu-DTPA-labelled peptide still
has binding afﬁnity for RXFP3 despite the presence of the large
DTPA/Eu+3 moiety. The Scatchard plot of the speciﬁc binding data
was linear (Fig. 4C inset), which is consistent with one-site bind-
ing of Eu-DTPA-R3 B1-22R with the receptor, RXFP3. The calculated
Kd and Bmax values are slightly different with the previous ligand
binding studies done in CHO-RXFP3 cell lines [54].
3.6. Competition binding of stapled peptidesOnce the Eu-DTPA-R3 B1-22R was  characterized by the satura-
tion binding experiments described above and determined to retain
binding afﬁnity for RXFP3, we  used the labelled ligand as a tracer
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Fig. 4. (A) Determination of the time course of europium (Eu) release from Eu-diethylenetriaminepentaacetic acid (DTPA)-R3 B1-22R. 10 l of 10 nM Eu-DTPA-R3 B1-22R
was  mixed with dissociation-enhanced lanthanide ﬂuorescent immunoassay (DELFIA) enhancement solution in triplicates and the ﬂuorescence was  measured at 5 min
intervals  for 60 min. The signal approached a maximum of approximately 2200 ﬂuorescent counts at 30 min. (B) Characterization of binding of Eu-DTPA-R3 B1-22R to RXFP3
in  HEK293T cells stably expressing RXFP3 (HEK-RXFP3). Total binding (circles) was  determined for increasing concentrations (range 0.5–128 nM)  of Eu-DTPA-R3 B1-22R
alone  while non-speciﬁc binding (squares) was  determined for the same range of concentration of Eu-DTPA-R3 B1-22R in the presence of 1 M unlabelled R3 B1-22R. The
measured ﬂuorescence counts were expressed as mean ± SEM (n = 3) of triplicate determinations from three independent experiments. (C) Kd and Bmax were determined by
ﬁtting a one-binding site model to the speciﬁc binding of Eu-DTPA-R3 B1-22R. Speciﬁc binding data were ﬁtted to Y =Bmax.X/(Kd + X). The Kd and Bmax value were determined
to  be 34.64 ± 3.83 SEM (n = 3) and 1061 ± 46.68 SEM (fmol/mg protein) (n = 3), respectively. A representative Scatchard plot (inset) shows a linear relationship between the
bound/free ratio and bound ligand, conﬁrming a one-site binding model for the binding of Eu-DTPA-R3 B1-22R with RXFP3. Data are presented as mean ± SEM of triplicates
from  three independent experiments. (D) Competition binding curves for relaxin-3 analogues in HEK-RXFP3 cells using Eu-DTPA-R3 B1-22R as the labelled ligand. Various
concentrations of (i) intact human relaxin-3 (1 pM to 10 M H3; green circles) and unlabelled R3 B1-22R (1 pM to 10 M R3 B1-22R; dark red) and (ii) the relaxin-3 B
chain  Cys10Ser + Cys22Ser double mutant (1 pM to 100 M B chain DM;  purple), the 18s22 stapled relaxin-3 B chain (1 pM to 100 M 18s22; orange) and the 14s18 stapled
relaxin-3 B chain (1 pM to 100 M 14s18; blue) were added to cells to compete for RXFP3 binding with 8 nM of Eu-DTPA-R3 B1-22R labelled ligand. Data are presented as
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For  interpretation of the references to color in this ﬁgure legend, the reader is refe
n competition binding assays (Fig. 4D) to study the interaction
f these receptors with their ligands. To rule out any signiﬁcant
ifference in agonist and antagonist binding modes, we ﬁrst stud-
ed the competition binding using various concentrations (1 pM to
0 M)  of unlabelled R3 B1-22R peptide and intact human relaxin-
 (Fig. 4Di). R3 B1-22R demonstrated a pKi of 7.24 ± 0.17 (n = 3),
hich is not signiﬁcantly different from intact human relaxin-3
ith a pKi of 7.38 ± 0.11 (n = 3) (p > 0.05 by one-way ANOVA and
ukey’s post hoc comparison; Table 2). In the similar manner, we
arried out the competition binding assay using various concentra-
ions (1 pM to 100 M)  of the stapled peptides (14s18 and 18s22)
nd the relaxin-3 B chain double mutant (Fig. 4Dii). The calculated
Ki values demonstrated a higher binding afﬁnity for the 14s18
tapled peptide (pKi = 6.42 ± 0.13) as compared to the relaxin-3
 chain double mutant peptide (pKi = 5.75 ± 0.24). The 18s22 sta-t shown for data points where the error bar is shorter than the height of the symbol.
 the web  version of this article.)
pled peptide had an intermediate binding afﬁnity (pKi = 6.02 ± 0.23)
between that of the relaxin-3 B chain double mutant peptide and
the 14s18 stapled peptide.
3.7. Intact human relaxin-3 mediated ERK1/2 activation can be
detected by an optimized ERK1/2 activation assay
Quantiﬁcation of the data revealed that the peak of ERK1/2 acti-
vation can be detected 8–10 min  post stimulation with 10 nM intact
human relaxin-3 in HEK-RXFP3 (Fig. 5A and B) and CHO-RXFP3
(Fig. 5C and D) cell lines by this method. However, ERK1/2 acti-
vation was observed neither in HEK293T (Fig. 5E) nor in CHO-K1
(Fig. 5F) cells with 10 nM intact human relaxin-3 at similar time
points.
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Fig. 5. The time course of ERK1/2 activation by 10 nM intact human relaxin-3 (H3) in (A) HEK-RXFP3 cells with (B) quantiﬁed relative density presented as activation of
ERK1/2,  (C) CHO-RXFP3 cells with (D) quantiﬁed relative density presented as activation of ERK1/2, (E) wild type HEK293T cells, and (F) wild type CHO-K1 cells. In (B) and
(D)  the quantiﬁed relative density activation of ERK1/2 is represented as mean ± SEM (n
corrected for multiple comparisons: *p < 0.05, **p < 0.01.
Table 2
Measures of binding afﬁnity and potency at RXFP3 receptors.
RXFP3 ligand Eu-DTPA-R3 B1-22R pKi RXFP3 cAMP pEC50
H3 7.38 ± 0.11 9.49 ± 0.14
R3 B1-22R 7.24 ± 0.17 n.d.
B  chain DM 5.75 ± 0.24 6.61 ± 0.24
18s22 6.02 ± 0.23 n.d.
14s18 6.42 ± 0.13 7.47 ± 0.16
Data are presented as the mean ± SEM (n = 3–4) of triplicates from three to four
independent experiments. H3: intact human rleaxin-3; B chain DM: relaxin-3 B
chain Cys10Ser + Cys22Ser double mutant; 18s22:18s22 stapled relaxin-3 B chain;
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(Fig. 8D). As the 14s18 stapled peptide had shown the greatest4s18: 14s18 stapled relaxin-3 B chain; n.d., not determined.
.8. Intact human relaxin-3 mediated inhibition of cAMP
ccumulation by RXFP3 can be detected by the inhibition of
orskolin-induced cAMP assay
Activation of adenylate cyclase by forskolin and inhibition of
denylate cyclase by Gi has been reported before [55,56]. An
nhibition of forskolin-induced cAMP assay revealed that, 10 nM
ntact human relaxin-3 is able to signiﬁcantly reduce the forskolin-
5 M)  induced cAMP levels in HEK-RXFP3 (Fig. 6A) and CHO-
XFP3 (Fig. 6C) cells as reported in previous publications [15].
owever, in wild type HEK293T (Fig. 6B) and CHO-K1 (Fig. 6D)
ells, 10 nM intact human relaxin-3 was not able to signiﬁcantly
educe the forskolin- (5 M)  induced cAMP levels. Meanwhile, in
he SN56 neuronal-like cell line, which expresses RXFP3, 100 nM
ntact human relaxin-3 was able to signiﬁcantly reduce forskolin-
3 M)  induced cAMP (Fig. 6E). = 3). Statistical analysis by one-way ANOVA followed by Dunnett’s post hoc test
3.9. Stapled B chains of relaxin-3 activate ERK1/2 in HEK-RXFP3
cells
The 18s22 stapled B chain of relaxin-3 was able to signiﬁcantly
activate ERK1/2 compared to the vehicle at a 10 M concentration
(Fig. 7C). However, 18s22 did not signiﬁcantly activate ERK1/2 at
100 nM and 1 M (Fig. 7A and B) although the statistical analysis did
not show a signiﬁcant difference in the ERK1/2 activation between
the intact human relaxin-3 (10 nM)  and the 100 nM and 1 M 18s22
treatments (Fig. 7A and B). The 14s18 stapled B chain of relaxin-
3 signiﬁcantly activated ERK1/2 at 10 M compared to the intact
human relaxin-3 (10 nM)  treatment (Fig. 7F) but not at 100 nM or
1 M (Fig. 7D and E).
3.10. Stapled relaxin-3 B chain peptides inhibit cAMP a cells
18s22 stapled relaxin-3 B chain signiﬁcantly inhibited the
forskolin (5 M)  induced cAMP levels at all the concentrations
tested (100 nM,  1 M and 10 M)  compared to the vehicle treat-
ment but did not show a clear dose-dependent effect (Fig. 8A–C).
Progressive reduction in the cAMP concentration was observed
with increasing stapled peptide concentrations. However, 14s18
stapled relaxin-3 B chain showed progressive, dose-dependent
reduction in the forskolin-induced cAMP levels signiﬁcant from
1 M onwards (Fig. 8E and F) while 100 nM 14s18 was not suf-
ﬁcient to signiﬁcantly inhibit the forskolin-induced cAMP levelstendency towards a clear dose-dependent effect, we  selected this
peptide for further analysis of the concentration-response relation-
ship with inhibition of forskolin-induced cAMP levels. Intact human
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Hig. 6. Inhibition of forskolin (FSK) induced cAMP assay by (A) 10 nM H3 relaxin (H
XFP3  cells (D) 10 nM H3 relaxin in CHO-K1 cells and (E) 100 nM H3 relaxin in SN5
y  one-way ANOVA followed by Tukey’s post hoc test corrected for multiple compa
elaxin-3 dose-dependently inhibited forskolin-induced cAMP lev-
ls with a pEC50 of 9.49 ± 0.14 in HEK-RXFP3 cells (Table 2) but
ave no signiﬁcant dose-dependent effect on forskolin-induced
AMP levels in wild type HEK293T cells (Fig. 8G). The relaxin-3
 chain double mutant was signiﬁcantly less potent with a pEC50
f 6.61 ± 0.24 in HEK-RXFP3 cells (Fig. 8H; Table 2). The 14s18
tapled peptide was signiﬁcantly more potent (p < 0.05, one-way
NOVA followed by Bonferroni multiple comparison’s test) than
he relaxin-3 B chain double mutant with a pEC of 7.47 ± 0.1650
n the HEK-RXFP3 cells (Table 2) but had no signiﬁcant dose-
ependent effect on forskolin-induced cAMP levels in wild type
EK293T cells (Fig. 8I).HEK-RXFP3 cells (B) 10 nM H3 relaxin in HEK293T cells (C) 10 nM H3 relaxin CHO-
. cAMP concentration in nM represented as mean ± SEM (n = 3). Statistical analysis
: *p < 0.05, **p < 0.01, ***p < 0.001.
4. Discussion
In this study, for the ﬁrst time, we  report that stapling of the
human relaxin-3 B chain at positions 18, 22 (18s22 stapled pep-
tide) and 14, 18 (14s18 stapled peptide) is able to retain biological
activity of the peptide.
In silico modelling had predicted that the 18s22 and 14s18 sta-
pled peptides would be feasible stapled peptides but that the 18s22
stapled peptide would be likely to be more rigid and helical. On
synthesis of the stapled peptides and determination of helicity
by analysis of CD spectra both 18s22 and 14s18 proved to have
-helical secondary structure but the CD analysis suggested that
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ensity is represented as mean ± SEM (n = 3). Statistical analysis by Kruskal-Wallis 
4s18 was more helical. Because i to i + 4 stapling holds the 3.6
esidues per turn of an -helix, it may  be that stapling at a more
entral position in the potentially helical domain of the relaxin-
 B chain in the 14s18 stapled peptide stabilizes the helix best.
D thermal stability analysis demonstrated that 14s18 was  able to
nfold and refold without losing the helical structure on refolding.
hese data are consistent with the hypothesis that hydrocarbon
tapling of the relaxin-3 B chain may  stabilise the peptide in an18s22, (D) 100 nM 14s18, (E) 1 M 14s18 and (F) 10 M 14s18. Quantiﬁed relative
llowed by Dunn’s multiple comparison test: *p < 0.05.
-helical conformation much like the A chain disulphide bonds
in human relaxin-3. Although hydrocarbon stapling stabilised the
-helical secondary structure of the peptide, certain residues can
induce helicity without the formation of a staple. In particular,
substitution with , amino acids, such as 2-aminoisobutyric acid
(Aib), is reported to increase helicity [57–60]. A major difference
between use of , amino acids without stapling and stapling is
that a staple may  impart more rigidity. It would interesting in
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Fig. 8. Inhibition of forskolin (FSK) induced cAMP assay in HEK-RXFP3 cells by (A) 100 nM 18s22 (B) 1 M 18s22 (C) 10 M 18s22 (D) 100 nM 14s18 (E) 1 M 14s18
and  (F) 10 M 14s18. cAMP concentration in nM represented as mean ± SEM (n = 3). (A)–(F) statistical analysis by one-way ANOVA followed by Bonferroni post hoc test:
*p  < 0.05, ***p < 0.001. Inhibition of forskolin (FSK) induced cAMP in HEK-RXFP3 cells (squares) and HEK293T cells (circles) by (G) 1 pM to 100 nM intact human relaxin-3
( B chai
c n ± SE
B
f
i
c
t
t
u
e
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c
t
c
iH3);  (I) 100 pM to 10 M relaxin-3 B chain Cys10Ser + Cys22Ser double mutant (
oncentration is represented as percentage of the forskolin-induced response (mea
ottom)/(1 + 10(ˆlogEC50-X)).
uture experiments to explore the correlations of helicity and rigid-
ty with function of relaxin-3 peptides. A proteolytic digestion assay
onﬁrmed that hydrocarbon stapling of the B chain increases pro-
eolytic stability of the peptide.
Both 18s22 and 14s18 stapled relaxin-3 B chain peptides bound
o RXFP3 receptors with greater afﬁnity than the corresponding
nstapled relaxin-3 B chain double mutant control peptide. How-
ver, the 14s18 stapled relaxin-3 B chain was more potent. It may
e that the greater helicity of the 14s18 stapled relaxin-3 B chain
onfers greater RXFP3 binding.
Relaxin-3-mediated RXFP3 activation leads to Gi/o coupling
o RXFP3 which results in ERK1/2 activation [15] and adenylate
yclase inhibition [6,15]. In order to determine the biological activ-
ty of the stapled B chains of relaxin-3, we optimized a Westernn DM); and (H) 100 pM to 10 M 14s18 stapled relaxin-3 B chain (14s18). cAMP
M; n = 3). Curves were ﬁt using a four-parameter Hill equation: Y = Bottom + (Top-
blot based ERK1/2 activation assay and an ELISA based inhibition of
forskolin-induced cAMP assay. Initially, we tested the reproducibil-
ity of the assays on few cell lines that overexpress or endogenously
express RXFP3, using the cognate ligand H3 relaxin. Results of these
assays conﬁrmed that relaxin-3 at 10 nM is able to signiﬁcantly acti-
vate RXFP3 in HEK-RXFP3 and CHO-RXFP3 cells. In the inhibition
of forskolin-induced cAMP assay, 10 nM H3 relaxin-3 was  able to
inhibit adenylate cyclase activity, which could not be overcome
by 5 M forskolin in HEK-RXFP3 and CHO-RXFP3 cells. Further
testing of the assays on wild type HEK293T and CHO-K1 cells con-
ﬁrmed the speciﬁcity of the response to RXFP3 indicating that this
assay can be used to detect Gi/o mediated cAMP inhibition related
signalling events in the cell lines tested. In SN56 cells, adenylate
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yclase inhibition was observed at 100 nM relaxin-3 which could
ot be overcome by 3 M forskolin.
We  sought to determine the ERK1/2 activation in both HEK-
XFP3 and CHO-RXFP3 cell lines, to conﬁrm whether the 8–10 min
ime point which is different to that reported in previous publica-
ions [15] is accurate, and to assess the robustness of the assay.
e observed that both cell lines show a peak ERK1/2 activa-
ion between 8 and 10 min. Further testing the assays on wild
ype HEK293T and CHO-K1 cells conﬁrmed the speciﬁcity of the
esponse to RXFP3.
We tested the stapled peptides for their ability to activate RXFP3
n HEK-RXFP3 cells. 18s22 stapled B chain of relaxin-3 was  able to
igniﬁcantly activate ERK1/2 in HEK-RXFP3 cells at 10 M.  Simi-
ar observation was made with 14s18 stapled B chain of relaxin-3,
here signiﬁcant ERK1/2 activation was observed with 10 M pep-
ide. Moreover, there is an increasing trend of ERK1/2 activation
rom 100 nM to 10 M for the 14s18 stapled peptide.
In the inhibition of forskolin-induced cAMP assay, 18s22 stapled
 chain of relaxin-3 was able to activate RXFP3 at the concentra-
ions tested (100 nM,  1 M and 10 M),  but 14s18 stapled B chain
f relaxin-3 was able to signiﬁcantly activate RXFP3 only at 1 M
nd 10 M concentrations. The 14s18 stapled relaxin-3 B chain
eptide dose-dependently inhibited forskolin-induced cAMP levels
ith greater potency than the corresponding unstapled relaxin-3
 chain double mutant control peptide.
The -helix is a common secondary structure found in pep-
ides. Stapling of -helices in peptides is the basis of developing
tapled peptides which is carried out mostly by hydrocarbon sta-
ling. This technique was ﬁrst reported by Verdine and co-workers
nd was used in developing BID BH3 peptides targeting the BCL-2
amily proteins [61]. These studies suggest that stapling of pep-
ides render them to be highly stable with increased helicity and
fﬁnity. The proteolytic stability of peptides and the blood brain
arrier permeability of peptide drugs limiting their usage in tar-
eting CNS disorders. Hydrocarbon stapling or modiﬁcations of
tapling chemistries may  increase proteolytic stability of peptides
nd enhance their ability to cross biological membranes and the
lood brain barrier. The relaxin-3 B chain loses its helicity in the
bsence of the A chain. Thus, stable analogues of relaxin-3 B chain
ill be useful tools in understanding its physiological signiﬁcance.
iven that relaxin-3 B chain possesses an -helix, it is amenable for
tapling. Therefore, we designed, synthesised and tested stapled B
hains of relaxin-3 to assess their biological activity.
In conclusion, stapling of the B chain of relaxin-3 at 18 and 22
ositions and 14 and 18 positions retain their ability to activate
XFP3 with regard to signalling events activated by RXFP3 activa-
ion such as Gi/o coupling and ERK1/2 activation. Thus, stapling
f the B chain of relaxin-3 is a promising method of developing
table agonists and antagonists of RXFP3 in order to overcome limi-
ations of using existing peptide agonists and antagonists in current
elaxin-3/RXFP3 research.
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